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Context
Type 2 diabetes mellitus (T2DM) is one of the most serious health pro-
blems worldwide.1 Strict glycaemic control has been emphasised, and the
number of patients with the risk of hypoglycaemia has increased.2
Hypoglycaemia is a serious side effect of treatment with sulphonylureas,
which stimulate insulin secretion regardless of blood glucose level. It is
more common in patients using long-acting sulphonylureas with renally
excreted active metabolites.3 Therefore, an increasing number of patients
with renal impairment may currently live with the risk of hypoglycaemia.
However, the incidence of hypoglycaemia when treating with sulphony-
lureas in patients with impaired renal function has remained unclear.
Methods
This was a population-based cohort study of the association between the
use of sulphonylureas and the risk of hypoglycaemia in relation to renal
function and sulphonylurea metabolite compared with the use of metfor-
min only. Data for this study were derived from the Clinical Practice
Research Datalink (CPRD) database, 2004–2012. Participants were new
users of a non-insulin antidiabetic agent. A ﬁrst ever hypoglycaemic
event was deﬁned as the ﬁrst ‘read code’ recording for hypoglycaemia or
a blood glucose level of <3.0 mmol/L. Sensitivity analyses by stratiﬁca-
tion of current users of metformin only by renal function were assessed,
as well as stratiﬁcation of current users of sulphonylureas only by daily
dose and haemoglobin A1c level.
Findings
The 120 803 participants (mean age 67.4 years) were followed-up for a
mean duration of 3.7 years. The current users of sulphonylureas only
showed a signiﬁcant increased risk of a hypoglycaemic event compared
with current users of metformin only (HR=2.50, 95% CI 2.23 to 2.82)
after the adjustment of the use of other non-insulin antidiabetic agents.
The risk of a hypoglycaemic event was dose-dependent in this compari-
son. The increase in risk of hypoglycaemia was also observed in patients
with current metformin and sulphonylurea use, as well as in patients
with current sulphonylurea and non-insulin antidiabetic agent use. In
patients with an estimated glomerular ﬁltration rate (eGFR) of <30 mL/
min/1.73 m2, the risk of hypoglycaemia in current users of sulphonylur-
eas only was markedly increased (HR=4.96, 95% CI 3.76 to 6.55). The use
of glibenclamide was associated with the highest risk of hypoglycaemic
events compared with the current use of metformin; other sulphonylureas
including gliclazide were also associated with increased risk.
Commentary
This study highlights the important debate on the use of sulphonylureas
and the risk of hypoglycaemia. It indicates that current users of sulpho-
nylureas only have a signiﬁcantly increased risk of hypoglycaemic
events compared with users of metformin only, and this is worsened in
renal impairment, and with increasing doses. Gliclazide, mainly excreted
as inactive metabolites, is the ﬁrst choice sulphonylurea for T2DM
because it is thought to have a lower risk of hypoglycaemia.4 However,
in this study, the use of gliclazide did not show a decreased risk of hypo-
glycaemia compared with glimepiride. As this study was based on real
life data in general clinical practice, unlike previous randomised con-
trolled trials (RCTs), there is the potential for selection bias with import-
ant differences in patient characteristics observed between groups. As
mentioned in the limitations of this study, patients with renal impairment
tended to be treated with gliclazide rather than other sulphonylureas with
active metabolites, limiting the power to be able to make comparisons.
Implications for practice
This study provided evidence that care should be taken in increasing
doses of sulphonylureas and that high-dose sulphonylurea treatment in
patients with renal impairment and an eGFR <30 mL/min/1.73 m2 should
be considered with caution. Gliclazide, the ﬁrst choice for sulphonylurea
in many countries based on presumption of lower risk of hypoglycaemia,
showed no different risks of hypoglycaemia compared with other sulpho-
nylureas in this study, highlighting the need for further investigation.
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